U.S. Markets close in 3 hrs 39 mins
  • S&P 500

    3,662.95
    +0.50 (+0.01%)
     
  • Dow 30

    29,804.40
    -19.52 (-0.07%)
     
  • Nasdaq

    12,337.85
    -17.25 (-0.14%)
     
  • Russell 2000

    1,829.14
    -6.90 (-0.38%)
     
  • Crude Oil

    45.78
    +1.23 (+2.76%)
     
  • Gold

    1,829.50
    +10.60 (+0.58%)
     
  • Silver

    24.06
    -0.03 (-0.15%)
     
  • EUR/USD

    1.2092
    +0.0013 (+0.1088%)
     
  • 10-Yr Bond

    0.9540
    +0.0200 (+2.14%)
     
  • Vix

    20.69
    -0.08 (-0.39%)
     
  • GBP/USD

    1.3351
    -0.0072 (-0.5394%)
     
  • USD/JPY

    104.4990
    +0.1830 (+0.1754%)
     
  • BTC-USD

    18,913.79
    -80.11 (-0.42%)
     
  • CMC Crypto 200

    370.61
    +5.69 (+1.56%)
     
  • FTSE 100

    6,463.39
    +78.66 (+1.23%)
     
  • Nikkei 225

    26,800.98
    +13.44 (+0.05%)
     

Penumbra Announces FDA Clearance of Indigo® Aspiration System for Treatment of Pulmonary Embolism

Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced U.S. Food and Drug Administration 510(k) clearance for expanded indication of the Indigo® Aspiration System. As part of the Indigo Aspiration System, the Indigo Aspiration Catheters and Separators are indicated for the removal of fresh, soft emboli and thrombi from vessels of the peripheral arterial and venous systems, and now, for the treatment of pulmonary embolism.

Penumbra introduced the Indigo System, a continuous aspiration mechanical thrombectomy system designed to remove clot from arteries and veins in the peripheral vasculature, in 2014. The Indigo System utilizes the Penumbra ENGINE™ aspiration source to deliver nearly pure, continuous vacuum suction to the Indigo System Aspiration Catheters to address emboli and thrombus in vessels of various sizes.

Important Safety Information

Additional information about Penumbra’s products can be located on Penumbra’s website at http://www.penumbrainc.com/healthcare-professionals. Prior to use, please refer to Instructions for Use for complete product indications, contraindications, warnings, precautions, potential adverse events and detailed instructions for use.

About Pulmonary Embolism

Pulmonary embolism (PE) is a condition that occurs when blood clots, typically traveling from the veins in the legs, get caught in the arteries of the lungs. Blood clots in the lungs can block the lungs from absorbing oxygen, causing strain on the heart and other organs. According to the American Heart Association, PE affects roughly 300,000 Americans per year.1

About Penumbra

Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets innovative products and has a broad portfolio that addresses challenging medical conditions and significant clinical needs across two major markets, neuro and vascular. Penumbra sells its products to hospitals primarily through its direct sales organization in the U.S., most of Europe, Canada and Australia, and through distributors in select international markets. Penumbra, the Penumbra P logo, Indigo, and Penumbra ENGINE are trademarks of Penumbra, Inc. For more information, visit www.penumbrainc.com.

Forward-Looking Statements

Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; and potential adverse regulatory actions. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission, including our Quarterly Reports on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2018. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.

Source: Penumbra, Inc.

1Benjamin, E.J. et al. on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation. 2019;139:e56–e528.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200109005056/en/

Contacts

Investor Relations
Penumbra, Inc.
510-995-2461
investors@penumbrainc.com

MEDIA CONTACT:
Joni Ramirez
Merryman Communications
joni@merrymancommunications.com
323-532-0746